第20回Population Pharmacokinetics研究会開催

Theme : Role of Population PK/PD Modeling and Simulation in Drug Development

Friday Oct 22
12:30 -13:45 Registration
13:45 -14:00 Opening Remark Hiroyasu Ogata
Tutorial chair : Hiroyasu Ogata
14:00 – 15:00 Russell Wada Improving the Quality of Clinical Development Using Computer-Assisted Trial Design (CATD)
15:00 – 15:20 Coffee Break
Oral Session I chair : Yukio Horai
15:20 – 15:50 Willi Weber Comparing efficacy of 10mg vs 20mg ARAVA in treatment of rheumatoidarthritis: A Population PK / PD Analysis
15:50 – 16:10 Mari Shiomi Population pharmacokinetic analysis of azithromycin using serum and tissue concentrations in healthy subjects and patients
16:10 – 16:30 Toshio Kawata Gefitinib / Preliminary population pharmacokinetic analysis from a nested case-control study
Oral Session II chair : Hisashi Nomura
16:30 – 16:50 Tomoo Funaki PK-PD oncology models in cancer chemotherapy
16:50 -17:10 Takeshi Tajima Pharmacokinetics/Pharmacodynamics of Basiliximab in renal transplantation
17:10 – 17:30 Shinichi Tsuchiwata Evaluation of estimated PK parameters and proportion for subgroup using Mixture option in NONMEM.
18:30－21:00 Social Evening and Poster Session (P-1～P-10)
Saturday Oct 23
Oral Session III and Tutorial chair : Naoko Kaniwa
9:00 － 9:25 Atsunori Kaibara, on behalf of Kansai PPK Benkyokai NONMEM Consistency Study(2)
9:25 – 10:05 Naomi Nagai 国際共同開発における臨床薬物動態の評価
10:05 – 10:30 Coffee Break
10:30 – 11:45 Panel Discussion chair : Yusuke Tanigawara and Yoshiro Tomono
Closing Remark (Planning of future PAGJA meeting) Hiroyasu Ogata
Poster Session
P-1 Bayer Yakuhin,Ltd. Takahiko Tanigawa Drug development with Modeling and Simulation -The most recent experience-
P-2 Eli Lilly Japan K.K. Kazunori Uenaka Comparison of the Efficacy, Safety and Pharmacokinetics of Raloxifene
Between Japanese and Caucasian Postmenopausal Women with Osteoporosis
P-3 Nippon Boehringer Ingelheim Co.,Ltd. Shinji Tatami Population Pharmacokinetics of Epinastine, a Histamine H1 Receptor Antagonist, in Adults and Children
P-4 Novartis Pharma K.K. Noriaki Kurata Pharmacokinetic aspects of Zoledronic acid
P-5 Otsuka Pharmaceutical Co., Ltd. Toshiko Koue The Pharmacokinetics of a New Antipsychotic, Aripiprazole in Healthy Adult Volunteers
P-6 Ono Pharmaceutical Co.,Ltd. Susumu Nakade Power estimation of a population pharmacokinetic study: as a case study
P-7 Pfizer Pharmaceuticals Inc. Sou Miyoshi The Application of Pharmacogenomic Approach and Population Pharmacokinetic Analysis to Clinical Development
P-8 Sankyo Co.,Ltd Kazutaka Yoshihara Population Pharmacokinetics of Olmesartan Medoxomil in Healthy Volunteers and Hypertensive Patients
P-9 Taiho Pharmaceutical Co., Ltd. Kenichiro Yoshida Estimation of recommendable dose of propiverine hydrochloride, in child popoulation suffering overactive bladder.
P-10 Tanabe Seiyaku Co.,Ltd. Takuya Okagaki A simulation work for comparison of ease-of-use between NONMEM and SAS NLMIXED Procedure (1)
– First Order and Adaptive Gaussian Quadrature Methods –